Clinical Trials Logo

Clinical Trial Summary

This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05204563
Study type Interventional
Source Evopoint Biosciences Inc.
Contact Yuanyuan Pan
Phone +86 0512-89162086
Status Recruiting
Phase Phase 3
Start date July 31, 2022
Completion date December 2025